Literature DB >> 16954555

Dosimetry in Peptide radionuclide receptor therapy: a review.

Marta Cremonesi1, Mahila Ferrari, Lisa Bodei, Giampiero Tosi, Giovanni Paganelli.   

Abstract

The potential of targeted therapy with radiolabeled peptides has been reported in several clinical trials. Although there have been many improvements in dose estimation, a general and reliable dosimetric approach in peptide receptor radionuclide therapy (PRRT) is still a matter of debate. This article reviews the methods for PRRT dosimetry and the results presented in the literature. Radiopharmaceutical characteristics, data processing, dosimetric outcomes, and methods to protect critical organs are reported. The biological effective dose, based on the linear quadratic model, is also described.

Mesh:

Substances:

Year:  2006        PMID: 16954555

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  57 in total

1.  Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres.

Authors:  Renaud Lhommel; Larry van Elmbt; Pierre Goffette; Marc Van den Eynde; François Jamar; Stanislas Pauwels; Stephan Walrand
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-27       Impact factor: 9.236

Review 2.  Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.

Authors:  Robert M Sharkey; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

Review 3.  Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

Authors:  Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-11       Impact factor: 9.236

Review 4.  A review on the clinical uses of SPECT/CT.

Authors:  Giuliano Mariani; Laura Bruselli; Torsten Kuwert; Edmund E Kim; Albert Flotats; Ora Israel; Maurizio Dondi; Naoyuki Watanabe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-25       Impact factor: 9.236

Review 5.  Time to demand dosimetry for molecular radiotherapy?

Authors:  D R McGowan; M J Guy
Journal:  Br J Radiol       Date:  2015-01-09       Impact factor: 3.039

6.  Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.

Authors:  Irina Velikyan; Thomas N Bulenga; Ramkumar Selvaraju; Mark Lubberink; Daniel Espes; Ulrika Rosenström; Olof Eriksson
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

Review 7.  Yttrium-labelled peptides for therapy of NET.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara M Grana; Marco Chinol; Silvia M Baio; Stefano Severi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

8.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Authors:  L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05       Impact factor: 9.236

9.  68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors.

Authors:  C Pettinato; A Sarnelli; M Di Donna; S Civollani; C Nanni; G Montini; D Di Pierro; M Ferrari; M Marengo; C Bergamini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-14       Impact factor: 9.236

10.  The role of patient-based treatment planning in peptide receptor radionuclide therapy.

Authors:  Deni Hardiansyah; Christian Maass; Ali Asgar Attarwala; Berthold Müller; Peter Kletting; Felix M Mottaghy; Gerhard Glatting
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-18       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.